PBA
URGN icon

Paradigm Biocapital Advisors’s UroGen Pharma URGN Stock Holding History

Paradigm Biocapital Advisors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,703,949
Closed -$30.6M – 38
2026
Q1 		$30.6M Sell
1,703,949
-2,769,699
-62% -$55.5M 0.63% 29
2025
Q4 		$105M Buy
4,473,648
+257,564
+6% +$5.59M 2.67% 13
2025
Q3 		$84.1M Buy
+4,216,084
New +$75.7M 2.39% 14

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Paradigm Biocapital Advisors's URGN Position: Q2 2026 in Review

Paradigm Biocapital Advisors sold out of UroGen Pharma (URGN) in Q2 2026, closing a stake of 1,703,949 shares — an estimated $30.6M sold.

Paradigm Biocapital Advisors first reported a position in URGN in Q3 2025 and held it in 3 quarters. The position peaked at $105M in Q4 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Paradigm Biocapital Advisors reported no remaining UroGen Pharma position as of Q2 2026 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 1,703,949 UroGen Pharma shares in Q2 2026, an estimated $30.6M.
  • Paradigm Biocapital Advisors first reported a position in UroGen Pharma in Q3 2025 and held it in 3 quarters.
  • Paradigm Biocapital Advisors's UroGen Pharma position peaked at $105M in Q4 2025.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.